Filing Details

Accession Number:
0001209191-17-024799
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-04-04 16:33:22
Reporting Period:
2017-03-31
Filing Date:
2017-04-04
Accepted Time:
2017-04-04 16:33:22
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1610618 Cidara Therapeutics Inc. CDTX () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1478831 Jeffrey Stein 6310 Nancy Ridge Drive
Suite 101
San Diego CA 92121
President & Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-03-31 12,900 $7.75 27,196 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Acquisiton 2017-03-31 220,000 $0.00 220,000 $7.80
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
220,000 2027-03-30 No 4 A Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 203,697 Indirect By trust
Common Stock 420 Indirect By son
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.50to $7.875, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities andExchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range setforth above.
  2. Includes 2,196 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on November 18, 2016.
  3. This holding, which was previously reported, was inadvertently omitted from the November 24, 2015 and May 20, 2016 Form 4 filings.
  4. The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 31, 2017.